A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
Starting soon · Phase 2
Conditions studied: Gastrointestinal Neoplasms
In brief
The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who progressed or were intolerant to standard therapies.
Key facts
- Study ID
- NCT07689201
- Run by
- GlaxoSmithKline
- People needed
- 24
- Starts
- 2026-08-31
- Expected to finish
- 2029-08-31
- Last updated by the study team
- 2026-07-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable.
- Documented disease progression on or intolerance to imatinib, sunitinib, regorafenib, and pimitespib.
- Documented mutation status of KIT and/or PDGFRA.
- Tumor tissue must be available for retrospective biomarker analysis. The sample may be from archival tissue or a new biopsy.
- Is willing to use adequate contraception male and/or female participants.
You may not qualify if…
- Known untreated or active central nervous system metastases.
- Has significant, uncontrolled, or active cardiovascular disease.
- Participants with a known allergy or hypersensitivity to any component of velzatinib. Participants with a history of Stevens-Johnson syndrome on a prior Tyrosine kinase inhibitor (TKI) are excluded.
- Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast, cervix, bladder] that have been resected with no evidence of metastatic disease.
- Prior treatment with ripretinib or other investigational agents that are currently under clinical development for GIST.
- Is pregnant or breastfeeding.
- Any condition or illness that, in the opinion of the Investigator, might compromise participant safety or interfere with the evaluation of the safety of the study treatment.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.